Pharmacogenomics in schizophrenia: The quest for individualized therapy

Human Molecular Genetics

Volumn 11, Issue 20, 2002, Pages 2517-2530

  Basile, Vincenzo S ^a   Masellis, Mario ^a   Potkin, Steven G ^b   Kennedy, James L ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUORODEOXYGLUCOSE F 18; NEUROLEPTIC AGENT;

BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; GENE FUNCTION; GENE INTERACTION; GENE TARGETING; GENE TECHNOLOGY; GENETIC VARIABILITY; HUMAN; INDIVIDUALIZATION; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEQUENCE ANALYSIS; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036796231     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/11.20.2517     Document Type: Review

References (119)

1. Seeman, P, Lee, T., Chau-Wong, M. and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopomine receptors. Nature, 261, 717-719.
2. APA (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington, DC.
3. Blechen, T. (1993) Clozapine: Literature Review. Sandoz Pharma, Basle.
4. 2A receptor gene. Lancet, 346, 281-282.
5. 2A receptor gene and response to clozapine. Mol. Psychiatry, 3, 61-66
6. 2A receptor and response to clozapine. Lancet, 346, 1108
7. Masellis, M., Basile, V, Meltzer, H.Y., Lieberman, J.A., Sevy, S., Macciardi, F.M., Cola, P., Howard, A., Badri, F., Nothen, M.M., et al. (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology, 19, 123-132.
8. 6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res., 47, 49-58.
9. 2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry, 153, 1092-1094.
10. 2C Cys(23)Ser polymorphism. Neuroreport, 7, 2100-2102.
11. 3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol. Psychiatry, 3, 72-75.
12. Ozdemir, V, Masellis, M., Basile, V.S., Kalow, W., Meltzer, H.Y., Lieberman, J.A. and Kennedy, J.L. (1999) Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. CNS Spectrums, 4, 30-56.
13. 4 receptor gene (DRD4) in schizophrenic patients. Am. J. Med. Genet. (Neuropsychiatric Genet.), 60, 541-545.
14. Masellis, M., Basile, V.S., Ozdemir, V., Meltzer, H.Y., Macciardi, F.M. and Kennedy, J.L. (2000) Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry, 47, 252-266.
15. Cichon, S., Nothen, M.M., Rietschel, M. and Propping, P. (2000) Pharmacogenetics of schizophrenia. Am. J. Med. Genet., 97, 98-106.
16. Andreasen, N.C. (1997) Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science, 275, 1586-1593.
17. Goldberg, T.E. and Gold, J.M. (1995) Neurocognitive deficits in schizophrenia. In Hirsch, S.R. and Weinberger, D.R. (eds), Schizophrenia. Blackwell, Oxford, p. 67.
18. Potkin, S.G., Fleming, K., Jin, Y. and Gulasekaram, B. (2001) Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol., 21, 479-483.
19. Masellis, M., Basile, V.S., DeLuca, V., Ni, X.-J., Meltzer, H.Y., Lieberman, J.A., Potkin, S.G. and Kennedy, J.L. (2002) Psychiatric pharmacogenetics of clozapine response: cleaning up a 'dirty drug'. Presented at the First Annual Pharmacogenetics in Psychiatry Meeting, New York.
20. Goldberg, T.E., Ragland, J.D., Torrey, E.F., Gold, J.M., Bigelow, L.B. and Weinberger, D.R. (1990) Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch. Gen. Psychiatry, 47, 1066-1072.
21. Cannon, T.D., Huttunen, M.O., Lonnqvist, J., Tuulio-Henriksson, A., Pirkola, T, Glahn, D., Finkelstein, J., Hietanen, M., Kaprio, J. and Koskenvuo, M. (2000) The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am. J. Hum. Genet., 67, 369-382.
22. Akil, M., Pierri, J.N., Whitehead, R.E., Edgar, C.L., Mohila, C., Sampson, A.R. and Lewis, D.A. (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry, 156, 1580-1589.
23. Weinberger, D.R., Berman, K.F. and Zec, R.F. (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry, 43, 114-124.
24. Weinberger, D.R., Berman, K.F. and Illowsky, B.P. (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry, 45, 609-615.
25. Kinon, B.J. and Lieberman, J.A. (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.), 124, 2-34.
26. Potkin, S.G., Basile, VS., Jin, Y., Masellis, M., Badri, F., Keator, D., Wu, J.C., Alva, G., Carreon, D.T., Bunney, W.E.J. et al. (2002) D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry, in press.
27. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C. and Weiden, P.J. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry, 156, 1686-1696.
28. Leadbetter, R., Shutty, M., Pavalonis, D., Vieweg, V, Higgins, P and Downs, M. (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry, 149, 68-72.
29. Umbricht, D.S., Pollack, S. and Kane, J.M. (1994) Clozapine and weight gain. J. Clin. Psychiatry, 55, 157-160.
30. Henderson, D.C., Cagliero, E., Gray, C., Nasrallah, R.A., Hayden, D.L., Schoenfeld, D.A. and Goff, D.C. (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry, 157, 975-981.
31. Meltzer, H.Y. (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci., 3, 64-75.
32. Comuzzie, A.G. and Allison, D.B. (1998) The search for human obesity genes. Science, 280, 1374-1377.
33. Wade, J., Milner, J. and Krondl, M. (1981) Evidence for a physiological regulation of food selection and nutrient intake in twins. Am. J. Clin. Nutr, 34, 143-147.
34. Basile, V.S., Masellis, M., McIntyre, R.S., Meltzer, H.Y., Lieberman, J.A. and Kennedy, J.L. (2001) Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry, 62, 45-66.
35. Blundell, J.E. (1984) Serotonin and appetite. Neuropharmacology, 23, 1537-1551.
36. Liebowitz, M.R., Hollander, E., Schneier, F., Campeas, R., Fallon, B., Welkowitz, L., Cloitre, M. and Davies, S. (1990) Anxiety and depression: discrete diagnostic entities? J. Clin. Psychopharmacol., 10, 61S-66S.
37. Wurtman, J., Wurtman, R., Berry, E., Gleason, R., Goldberg, H., McDermott, J., Kahne, M. and Tsay, R. (1993) Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology, 9, 201-210.
38. Davis, R. and Faulds, D. (1996) Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs, 52, 696-724.
39. Yamada, J., Sugimoto, Y., Yoshikawa, T., Noma, T. and Horisaka, K. (1996) The effects of peripheral serotonin2 receptor agonist on food intake of rats. Adv. Exp. Med. Biol., 398, 555-557.
40. Pazos, A., Probst, A. and Palacios, J.M. (1987) Serotonin receptors in the human brain - III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience, 21, 97-122.
41. Pazos, A., Probst, A. and Palacios, J.M. (1987) Serotonin receptors in the human brain - IV Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 21, 123-139.
42. 2C serotonin receptors. Nature, 374, 542-546.
43. Baptista, T (1999) Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scand., 100, 3-16.
44. Morimoto, T., Yamamoto, Y., Mobarakeh, J.I., Yanai, K., Watanabe, T. and Yamatodani, A. (1999) Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav., 67, 679-683.
45. Wirshing, D.A., Spellberg, B.J., Erhart, S.M., Marder, S.R. and Wirshing, W.C. (1998) Novel antipsychotics and new onset diabetes. Biol. Psychiatry, 44, 778-783.
46. Stahl, S.M. (1998) Neuropharmacology of obesity: my receptors made me eat it. J. Clin. Psychiatry, 59, 447-448.
47. Sakata, T., Kang, M., Kurokawa, M. and Yoshimatsu, H. (1995) Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Obes. Res., 3 (Suppl. 5), 707S-712S.
48. Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J., Mintz, J. and Marder, S.R. (1999) Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry, 60, 358-363.
49. Cummings, D.E., Brandon, E.P., Planas, J.V, Motamed, K., Idzerda, R.L. and McKnight, G.S. (1996) Genetically lean mice result from targeted disruption of the RII β subunit of protein kinase A. Nature, 382, 622-626.
50. Clapham, J.C., Arch, J.R., Chapman, H., Haynes, A., Lister, C., Moore, G.B., Piercy, V, Carter, S.A., Lehner, I., Smith, S.A. et al. (2000) Mice overexpressing human uncoupling protem-3 in skeletal muscle are hyperphagic and lean. Nature, 406, 415-418.
51. 2C receptor gene polymorphism. Lancet, 359, 2086-2087.
52. 2C receptor gene and their association with obesity and type II diabetes. Diabetologia, 43, 373-376.
53. Basile, VS., Masellis, M., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L. (2002) Serotonin 2C receptor gene and clozapine-induced weight gain. Lancet, in press.
54. Rosengarten, H., Schweitzer, J.W. and Friedhoff, A.J. (1993) A mechanism underlying neuroleptic induced oral dyskinesias in rats. Pol. J. Pharmacol., 45, 391-398.
55. 1 receptors mediate repetitive jaw movements in rats. Pharmacol. Biochem. Behav., 45, 921-924.
56. Muller, D.J., Schulze, T.G., Knapp, M., Held, T., Krauss, H., Weber, T., Ahle, G., Maroldt,. A., Alfter, D., Maier, W. et al. (2001) Familial occurrence of tardive dyskinesia. Acta Psychiatr. Scand. 104, 375-379.
57. Meshul, C.K. and Casey, D.E. (1989) Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res., 489, 338-346.
58. Smith, J.M. and Baldessarini, R.J. (1980) Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch. Gen. Psychiatry, 37, 1368-1373.
59. Kane, J.M. and Smith, J.M. (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry, 39, 473-481.
60. Jeste, D.V., Lindamer, L.A., Evans, J. and Lacro, J.P. (1996) Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol. Bull., 32, 243-251.
61. Yassa, R. and Jeste, D.V. (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull., 18, 701-715.
62. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res., 779, 58-74.
63. 3 preferring compounds in discrete areas of the rat brain. J. Neural Transm. Gen. Sect., 102, 209-220.
64. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl Acad. Sci. USA, 93, 1945-1949.
65. Meador-Woodruff, J.H., Haroutunian, V, Powchik, P., Davidson, M., Davis, K.L. and Watson, S.J. (1997) Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch. Gen. Psychiatry, 54, 1089-1095.
66. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatric Genet., 2, 249-256.
67. 3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun., 225, 1068-1072.
68. Badri, F., Masellis, M., Petronis, A., Macciardi, F.M., Van Tol, H.H.M., Cola, P., Meltzer, H.Y., Lieberman, J., Potkin, S. and Kennedy, J.L. (1996) Dopamine and serotonin system genes may predict clinical response to clozapine. (In Proceedings of the 46th Annual Meeting of the American Society of Human Genetics.) Am. J. Hum. Genet., 59(Suppl), A247.
69. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry, 2, 139-145.
70. 3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology, 21, 17-27.
71. 3 receptor and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry, 4, 247-253.
72. 3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 44, 95-98.
73. 3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int. J. Neuropsychopharmacol, 3, 61-65.
74. 3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin. Neurosci., 56, 469-474.
75. Inada, T., Dobashi, I., Sugita, T., Inagaki, A., Kitao, Y., Matsuda, G., Kato, S., Takano, T., Yagi, G. and Asai, M. (1997) Search for a susceptibility locus to tardive dyskinesia. Hum. Psychopharmacol. Clin. Exp., 12, 35-39.
76. 3 receptor variant and tardive dyskinesia. Eur. Arch. Psychiatry Clin. Neurosci, 250, 31-35.
77. 3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J. Neural Transm., 108, 671-677.
78. 3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology, 27, 105-119.
79. Segman, R.H., Heresco-Levy, U., Finkel, B., Goltser, T, Shalem, R., Schlafman, M., Dorevitch, A., Yakir, A., Greenberg, D., Lerner, A. and Lerer, B. (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry, 6, 225-229.
80. Tan, E.C., Chong, S.A., Mahendran, R., Dong, F. and Tan, C.H. (2001) Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol. Psychiatry, 50, 144-147.
81. Basile, VS.., Ozdemir, V., Masellis, M., Meltzer, H.Y., Lieberman, J.A., Potkin, S.G., Macciardi, F.M., Petronis, A. and Kennedy, J.L. (2001) Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol. Psychiatry, 6, 230-234.
82. Potkin, S.G., Kennedy, J.L. and Basile, VS. (2002) Combining brain imaging and pharmacogenetics in understanding clinical response in Alzheimer's disease and schizophrenia. In Lerer, B. (ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge University Press.
83. Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1999) Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 47, 445-449.
84. Basile, V.S., Ozdemir, V, Masellis, M., Walker, M.L., Meltzer, H.Y., Lieberman, J.A., Potkin, S.G., Alva, G., Kalow, W., Macciardi, F.M. and Kennedy, J.L. (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry, 5, 410-417.
85. Schulze, T.G., Schumacher, J., Muller, D.J., Krauss, H., Alfter, D., Maroldt, A., Able, G., Maroldt, A.O., Novo y Fernandez, A., Weber, T. et al. (2001) Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet., 105, 498-501.
86. Frankel, W.N. and Schork, N.J. (1996) Who's afraid of epistasis? Nat. Genet., 14, 371-373.
87. Rietschel, M., Kennedy, J.L., Macciardi, F.M., DeLisi, L., Meltzer, H.Y. and the Consensus Group for Outcome Measures in Psychoses for Pharmacogenetic Studies (1999) Pharmacogenetics in Psychosis, the First Consensus Conference. Schizophrenia Res., 37, 191-196.
88. Shan, D.E., Liao, K.K. and Fuh, J.L. (1998) Clinical manifestations of tardive truncal dystonia-abdominal movements: report of two cases. Chung Hua I Hsueh Tsa Chih (Taipei), 61, 545-550.
89. Leboyer, M., Bellivier, F., Nosten-Bertrand, M., Jouvent, R., Pauls, D. and Mallet, J. (1998) Psychiatric genetics: search for phenotypes. Trends Neurosci, 21, 102-105.
90. Serretti, A., Macciardi, F. and Smeraldi, E. (1996) Identification of symptomatologic patterns common to major psychoses: proposal for a phenotype definition. Am. J. Med. Genet., 67, 393-400.
91. Wassink, T.H., Nelson, J.J., Crowe, R.R. and Andreasen, N.C. (1999) Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am. J. Med. Genet., 88, 724-728.
92. 2 receptor gene. Mol. Psychiatry, 3, 261-265.
93. Hariri, A.R., Mattay, V.S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M.F. and Weinberger, D.R. (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science, 297, 400-403.
94. Arranz, M.J., Li, T., Munro, J., Liu, X., Murray, R., Collier, D.A. and Kerwin, R.W (1998) Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics, 8, 481-484.
95. 4 receptor gene (DRD4) in schizophrenic patients. Am. J. Med. Genet. (Neuropsychiatric Genet.), 60, 541-545.
96. 3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol., 10, 17-20.
97. 4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry, 51, 912-917.
98. 4 receptor gene. Neuropsychopharmacology, 15, 491-496.
99. 4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur. Neuropsychopharmacol., 7, 39-43.
100. 4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol. Psychiatry, 5, 418-424.
101. 2A receptor and response to clozapine. Lancet, 346, 908-909.
102. 2A receptor T102C polymorphism and schizophrenia. Lancet, 347, 1831-1832.
103. Lin, C.H., Tsai, S.J., Yu, Y.W., Song, H.L., Tu, P.C., Sim, C.B., Hsu, C.P., Yang, K.H. and Hong, C.J. (1999) No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport, 10, 57-60.
104. 2C receptor gene. Neuroreport, 7, 169-172.
105. 2C receptor. Neuroreport, 8, 1999-2003.
106. Yu, Y.W., Tsai, S.J., Lin, C.H., Hsu, C.P, Yang, K.H. and Hong, C.J. (1999) Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport, 10, 1231-1233.
107. Tsai, S.J., Hong, C.J., Yu, Y.W., Lin, C.H., Song, H.L., Lai, H.C. and Yang, K.H. (2000) Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr. Res., 44, 177-181.
108. Chen, C.H., Wei, F.C., Koong, F.J. and Hsiao, K.J. (1997) Association of TaqIa polymorphism of dopamine D-2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry, 41, 827-829.
109. 2 receptor gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet., 105, 774-778.
110. Segman, R.H., Heresco-Levy, U., Finkel, B., Inbar, R., Neeman, T., Schlafman, M., Dorevitch, A., Yakir, A., Lerner, A., Goltser, T. et al. (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl.), 152, 408-413.
111. Arthur, H., Dahl, M.L., Siwers, B. and Sjoqvist, F. (1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol., 15, 211-216.
112. Armstrong, M., Daly, A.K., Blennerhassett, R., Ferrier, N. and Idle, J.R. (1997) Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br. J. Psychiatry, 170, 23-26.
113. Andreassen, O.A., MacEwan, T., Gulbrandsen, A.K., McCreadie, R.G. and Steen, V.M. (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology, 131, 174-179.
114. Kapitany, T., Meszaros, K., Lenzinger, E., Schindler, S.D., Barnas, C., Fuchs, K., Sieghart, W., Aschauer, H.N. and Kasper, S. (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Res., 32, 101-106.
115. Ohmori, O., Suzuki, T., Kojima, H., Shinkai, T., Terao, T., Mita, T. and Abe, K. (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophrenia Res., 32, 107-113.
116. Ohmori, O., Kojima, H., Shinkai, T., Terao, T., Suzuki, T. and Abe, K. (1999) Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res., 87, 239-244.
117. Hori, H., Ohmori, O., Shinkai, T., Kojima, H., Okano, C., Suzuki, T. and Nakamura, J. (2000) Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology, 23, 170-177.
118. Zhang, Z., Zhang, X., Hou, G., Sha, W. and Reynolds, G.P. (2002) The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr Res., 36, 317-324.
119. 6 receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res., 110, 97-102.